Leucine-rich alpha-2 glycoprotein 1 (LRG1) is a multifunctional plasma protein present at concentrations of 21–50 μg/mL in healthy individuals. As an acute-phase protein, LRG1 levels rise significantly during bacterial infections and various inflammatory conditions, but its regulation is independent of traditional markers like C-reactive protein (CRP). LRG1 plays a key role in modulating immune and vascular responses, acting as an upstream regulator of the TGF-β signaling pathway and promoting angiogenesis by influencing endothelial cell behavior. It binds cytochrome c, a molecule involved in apoptosis, thereby potentially supporting cell survival during tissue injury and inflammation.
Elevated LRG1 is recognized as a biomarker for multiple cancers-including non-small cell lung, colorectal, pancreatic, and ovarian cancer-where it correlates with disease progression and prognosis. Beyond oncology, LRG1 is implicated in cardiovascular, renal, autoimmune, and neurodegenerative diseases, such as Parkinson’s disease, and is being explored as a diagnostic and therapeutic target due to its roles in inflammation, vascular dysfunction, and tissue remodeling.
Common uses include IVD Assay standards, calibrators and controls, therapeutics research, immune system research.
Not a hazardous substance or mixture.
11 - Combustible Solids